Deadly Candida Auris Fungal Infections Are on the Rise

If you’ve never heard of Candida auris before, don’t feel bad – most people can’t
pronounce it, let alone spell it. Unfortunately, this tongue-twisting yeast has gone from a medical
footnote to a global headline in just over a decade. Health agencies now call it an
urgent public health threat because it’s drug-resistant, hard to kill, tricky to
diagnose, and more common every year in hospitals and long-term care facilities.

That might sound like the pitch for a medical thriller, but this is very real. Since the first
recognized U.S. case in the mid-2010s, reported Candida auris infections have increased
dramatically, with thousands of new clinical cases recorded in a single year. Behind those numbers
are very sick patients, overwhelmed healthcare workers, and infection-prevention teams racing to
stop an invisible invader that clings to skin, survives on surfaces, and shrugs off multiple
antifungal drugs.

In this in-depth guide, we’ll break down what Candida auris is, why infections are
rising, who is most at risk, how it’s treated, and what hospitals and families can do to reduce the
danger. We’ll keep the science accurate but the language human because you shouldn’t need a
microbiology degree to understand a fungus that’s trying very hard to become famous.

What Is Candida Auris, and Why Are Experts Worried?

A stealthy, stubborn yeast

Candida auris (often shortened to C. auris) is a species of yeast
a type of fungus first identified in 2009. Unlike the more familiar
Candida albicans, which can cause common infections like vaginal yeast infections or oral
thrush, C. auris has a much darker personality. It’s considered an
emerging, multidrug-resistant pathogen that can invade the bloodstream and internal
organs, causing severe illness in already vulnerable patients.

Several features make C. auris especially concerning:

• Multidrug resistance: Many strains are resistant to one or more major classes
  of antifungal medications, and some are resistant to all of them.
• Hard to identify: Standard lab methods can misidentify it as another, less
  dangerous yeast, leading to delays in proper treatment and infection control.
• Persistent in the environment: It hangs out on surfaces and equipment, surviving
  for weeks if disinfection isn’t effective.
• Easily spreads in healthcare settings: It can pass from patient to patient via
  hands, gloves, gowns, and contaminated devices.

Put simply, this is not your everyday “take a pill and move on” fungal infection. It’s more like
the bad roommate of the microbial world: it shows up uninvited, refuses to leave, and ignores most
of the usual hints to get out.

How Fast Are Candida Auris Infections Rising?

From rare curiosity to thousands of cases

When U.S. health officials first started tracking Candida auris around 2016,
reported numbers were tiny dozens of clinical cases per year. That didn’t last. In just a few
years, cases grew into the hundreds, then thousands. By 2023, data from U.S. public health agencies
showed more than 4,500 new clinical cases in a single year, and the upward trend
has continued with additional cases reported in 2024 and 2025.

Several states including New York, Florida, California, Nevada, Illinois, and parts of the
Southeast have reported particularly high numbers of cases and outbreaks linked to hospitals and
long-term care facilities. Globally, C. auris has now been detected on nearly every
continent, and the World Health Organization has flagged it as a critical priority
pathogen due to its resistance and outbreak potential.

Why are the numbers climbing?

The rise in C. auris infections isn’t just about better testing – though improved lab
tools do play a role. Several factors are driving the increase:

• More vulnerable patients: Modern medicine saves people with serious illnesses,
  but intensive care units, transplants, chemotherapy, and long-term ventilation all increase the
  number of people with weakened immune systems and invasive devices.
• Heavy antifungal and antibiotic use: Widespread use of antifungal drugs and
  antibiotics can wipe out beneficial microbes and favor resistant organisms like C. auris.
• COVID-19-era pressure: Overcrowded ICUs, staffing shortages, and strained
  infection control during the COVID-19 pandemic helped opportunistic organisms, including
  drug-resistant fungi, spread more easily.
• Global movement: Patients transfer between facilities and even across borders,
  potentially carrying C. auris with them without anyone realizing it.

All of this adds up to a simple reality: once Candida auris gains a foothold in a healthcare
system, it’s tough to push it back out without aggressive screening, cleaning, and coordination.

Who Is Most at Risk of Candida Auris Infection?

Not a big threat to healthy people, but dangerous for fragile patients

For most healthy people walking around, Candida auris is not an everyday danger.
You won’t catch it from grabbing a shopping cart or sitting on a park bench. The real risk is in
healthcare environments and among people who are already seriously ill.

The highest risk groups include:

• Patients in intensive care units (ICUs)
• People with central lines, feeding tubes, or urinary catheters
• Individuals on ventilators or other complex devices
• Residents of long-term care facilities, especially those needing extensive
  hands-on care
• People with weakened immune systems (e.g., cancer, transplant, advanced chronic
  diseases)
• Patients receiving multiple antibiotics or antifungal drugs

Many people with C. auris are “colonized” meaning the fungus lives on their skin or in
body sites without making them feel sick. That colonization still matters, because colonized
patients can spread the fungus to others or later develop invasive infection if their health
worsens.

Symptoms and Complications: What Does Candida Auris Do?

Subtle symptoms, serious consequences

There’s no single “Candida auris rash” or unique symptom that gives it away. Instead, symptoms
depend on where the infection occurs and usually look a lot like other serious infections:

• Bloodstream infection: fever, chills, low blood pressure, confusion, signs of
  sepsis, organ dysfunction
• Wound infection: redness, swelling, discharge, delayed healing
• Ear or other localized infections: pain, discharge, or inflammation in the
  affected area

Because many C. auris patients are already critically ill, it can be hard to tell what’s
causing new symptoms. That’s why the diagnosis depends heavily on lab testing blood cultures and
other specimens that are correctly processed and identified with modern methods.

The most serious concern is invasive bloodstream infection, which can lead to
multi-organ failure and death. Studies have reported mortality rates of roughly
30–60% in severely ill patients with invasive C. auris, although the exact
risk varies by population, underlying illness, and access to effective treatment.

Why Is Candida Auris So Hard to Treat?

Drug resistance and limited options

Most fungal infections respond to one of three major classes of antifungal drugs. With
Candida auris, things get complicated. Many strains are resistant to the
azole class (like fluconazole). Some also resist amphotericin B,
a powerful but toxic drug often used for severe fungal infections. A few strains are even
pan-resistant, meaning they show resistance to all three main antifungal classes.

The current first-line treatment for most C. auris infections is a class of drugs called
echinocandins. These medications target the fungal cell wall and are generally well
tolerated. However, resistance to echinocandins has also been reported, especially in patients who
receive prolonged or repeated courses of therapy.

When infection doesn’t respond, specialists may use combination therapy or newer
antifungal agents still being studied. Treatment decisions are often guided by:

• Antifungal susceptibility testing from the lab (to see which drugs might still work)
• The patient’s underlying conditions and kidney or liver function
• Site of infection (bloodstream, wound, deep organ)
• How quickly the patient is improving or worsening

This is not a “one size fits all” situation. Managing Candida auris usually requires an
infectious-disease specialist, careful monitoring, and sometimes tough choices between imperfect
options.

Important note: Anyone who thinks they or a loved one might have a serious
infection should seek immediate medical care. Online information is helpful for understanding the
issue, but it can’t replace diagnosis and treatment from qualified professionals.

How Does Candida Auris Spread in Healthcare Settings?

From skin to surfaces to equipment

Candida auris is primarily a contact-transmitted pathogen. It
doesn’t fly through the air like measles or spread through casual community contact. Instead, it
spreads mainly via:

• Skin-to-skin contact with colonized or infected patients
• Hands of healthcare workers if hand hygiene isn’t done correctly
• Contaminated equipment such as blood pressure cuffs, ventilators, catheters,
  and shared medical devices
• Environmental surfaces like bed rails, bedside tables, call buttons, and
  doorknobs that are not properly disinfected

Because C. auris can survive for long periods on surfaces and isn’t killed by many
standard disinfectants, once it gets into a healthcare facility, it can cause persistent
outbreaks unless facilities tighten up infection control procedures.

Preventing and Controlling Candida Auris in Hospitals

The infection-prevention “toolkit”

The good news: while Candida auris is tough, it’s not unstoppable. Healthcare
facilities can significantly reduce spread by using a coordinated infection-prevention strategy.
Key elements include:

• Early detection and lab capacity
  Facilities need access to labs that can accurately identify C. auris using methods like
  MALDI-TOF or molecular tests. Rapid identification allows faster isolation and targeted
  cleaning.
• Contact precautions
  Patients with known or suspected C. auris are often placed in single rooms or cohorted,
  with staff using gowns and gloves and following strict hand hygiene.
• Hand hygiene (over and over again)
  Consistent hand cleaning with alcohol-based rubs or soap and water when visibly soiled is
  essential to break the chain of transmission.
• Environmental cleaning and disinfection
  Not all disinfectants work against C. auris. Facilities must use
  EPA-registered products proven to kill it and ensure thorough cleaning of
  high-touch surfaces and shared equipment.
• Screening and surveillance
  Some hospitals screen high-risk patients (such as transfers from facilities with known
  outbreaks) to detect colonization early.
• Communication between facilities
  When patients are transferred, their C. auris status should be clearly communicated so
  the receiving facility can continue appropriate precautions.
• Education and audits
  Ongoing staff training and regular audits of hand hygiene and cleaning practices help keep
  infection control from slipping as workloads rise.

It’s not glamorous work, but these basics are the backbone of stopping C. auris. Think of
them as the “eat your vegetables” of hospital safety: not flashy, but absolutely essential.

What Can Patients and Families Do?

Practical steps without panic

Hearing about a “deadly, drug-resistant fungus” is unsettling, especially if someone you love is in
the hospital. While most of the heavy lifting happens at the facility level, patients and families
can still play a role in safety:

• Ask about infection control: It’s okay to ask staff if they’ve cleaned their
  hands before touching you or your loved one.
• Pay attention to devices: If a dressing is loose, a catheter site looks
  red, or equipment looks dirty, speak up.
• Follow visitor rules: Wear gowns, gloves, or masks if instructed, and clean
  your hands when entering and leaving the room.
• Stay informed: If the term “Candida auris” appears in a medical discussion,
  ask what it means in the specific context of the patient’s case.

Feeling like a partner in care, rather than just a bystander, can make a huge emotional difference
and sometimes a clinical one too.

Looking Ahead: The Future of Candida Auris

The rise of Candida auris is part of a larger story about antimicrobial resistance.
Bacteria, fungi, and other pathogens are adapting faster than we’re developing new drugs. That
doesn’t mean we’re helpless, but it does mean we need to take this seriously:

• Investing in better diagnostics to detect resistant organisms quickly
• Developing new antifungal medications and combination therapies
• Improving infection prevention in every type of facility, from small nursing homes to large
  academic hospitals
• Using antibiotics and antifungals more judiciously so we don’t accelerate
  resistance unnecessarily

Candida auris might not be a household name yet, but in infection-control circles, it’s
already notorious. The goal now is to keep it from becoming even more common and to make sure
vulnerable patients get the best protection and care we can offer.

Real-World Experiences With Candida Auris

A night in the ICU: a nurse’s perspective

To understand what the rise of Candida auris feels like on the ground, imagine a
night shift in a busy intensive care unit. Beds are full, alarms are sounding, and a nurse is
juggling patients on ventilators, multiple drips, and complex treatment plans. At 2 a.m., the lab
calls: one of her patients’ blood cultures has tested positive for C. auris.

Immediately, the atmosphere changes. The charge nurse pulls out the infection-control playbook:
contact precautions, room signage, extra gowns and gloves, special disinfectants. Environmental
services is called for a more intensive room cleaning. The nurse has to adjust her mental checklist
every time she enters and leaves the room, every line she touches, every piece of equipment she
shares must be treated as a possible vehicle for this stubborn fungus.

None of this is theoretical. Nurses and other frontline staff in facilities with C. auris
outbreaks describe a constant balancing act: caring compassionately for critically ill patients
while never switching off their awareness of what might be hiding on a surface, a glove, or a
blood-pressure cuff. The work can be emotionally exhausting, but many also describe a sense of
pride when they see outbreak numbers stabilize, knowing their extra efforts helped keep
transmission in check.

A family’s story: learning a new vocabulary

For families, the first time they hear the words “Candida auris” is often during an
already stressful hospital stay. A daughter sitting at her mother’s bedside may notice new signs on
the door, more staff coming in with gowns and gloves, and extra cleaning equipment rolling down the
hall. When she asks what’s going on, someone explains that a culture came back positive for a
“drug-resistant fungus.”

At first, the jargon can be overwhelming: colonization versus infection, contact precautions,
susceptibility testing. Many families describe Googling the term on their phones and feeling a jolt
of fear when they see phrases like “deadly” and “urgent threat.” The most helpful experiences
typically involve a calm clinician sitting down, explaining that:

• Her mother is already in the right place to receive treatment and monitoring.
• The precautions are there to protect both her mother and other patients.
• Not every C. auris culture means a fatal infection context matters.

Families often feel more in control once they know what they can do: clean their hands, follow
visitor precautions, speak up if something seems off, and ask for regular updates from the care
team. Over time, the strange new term becomes part of the story of a hospital stay one more
challenge in a journey they never expected to take, but are determined to face as a team.

Inside infection control: chasing invisible patterns

Infection-prevention specialists sometimes describe their work with Candida auris
as “detective work with a microscope.” When new cases appear, they map out timelines, room
assignments, staff rosters, and device use, looking for patterns. Did multiple patients with
C. auris share the same hallway? The same ultrasound machine? The same dialysis unit?

In one hypothetical but very realistic scenario, a hospital notices that several patients in a
long-term acute-care wing test positive for C. auris over a few weeks. None of them were
positive on admission. Reviewing workflows, the team discovers that a portable blood pressure cuff
was being moved from room to room without proper disinfection. Once they change the protocol and
intensify cleaning, new cases slow down.

These kinds of experiences highlight an important truth: the rise of Candida auris is not
just about microorganisms and medications. It’s also about systems, habits, communication, and
attention to detail. Infection-prevention teams talk about building a “culture of safety,” where
everyone from physicians to housekeeping staff understands their role in stopping the spread of
drug-resistant organisms.

Why these stories matter

Stories from nurses, families, and infection-control professionals put a human face on the statistics.
When you read about thousands of Candida auris infections, it’s easy to picture an
abstract curve on a graph. But each data point represents a real person, a real family, and a real
group of caregivers doing their best under intense pressure.

As C. auris continues to spread, these lived experiences can help shape better policies and
practices. They remind us that breakthrough drugs and high-tech diagnostics are crucial, but so are
basics like clear communication, emotional support, and a relentless commitment to hand hygiene and
environmental cleaning. That combination science plus everyday actions is our best defense
against a fungus that very much wants to stay.